Cogent Biosciences Inc
Ownership
Ownership Structure
Who owns Cogent Biosciences Inc (COGT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 112.3%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 13.33 | 23,122,748 | +0.2 | 03/31/2026 |
| BlackRock Inc | 9.25 | 16,045,014 | +23.7 | 03/31/2026 |
| Deerfield Management Co | 5.21 | 9,043,903 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.23 | 7,333,333 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.97 | 6,894,959 | +0.0 | 03/31/2026 |
| HHG PLC | 3.44 | 5,965,125 | +31.5 | 03/31/2026 |
| State Street Corp | 3.26 | 5,663,543 | +14.6 | 03/31/2026 |
| Fairmount Funds Management LLC | 3.17 | 5,503,418 | -38.9 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 3.15 | 5,458,675 | -28.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.98 | 5,175,246 | +0.3 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Morris Arlene | Director | Sell | 3,161 | 37.54 | 118,663 |
| Aug 27, 2026 | Morris Arlene | Director | Sell | 42,349 | 37.09 | 1,570,830 |
| Aug 27, 2026 | Morris Arlene | Director | Other | 3,583 | 2.52 | 9,029 |
| Aug 27, 2026 | Morris Arlene | Director | Other | 41,927 | 5.64 | 236,468 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.